Wellington Partners invested $53 million in ImCheck Therapeutics' Series B financing to support the clinical development of novel immunotherapies targeting cancer.
Target Information
ImCheck Therapeutics is an innovative biotech company focused on pioneering a first-in-class antibody designed to activate gamma delta (γδ) T cells, targeting a variety of cancer indications. The company is committed to developing a robust portfolio of novel immunotherapies aimed at treating not only cancer but also autoimmune diseases.
Recently, ImCheck announced the successful closure of its $53 million (€48 million) Series B financing round. The funds raised will enable the company to initiate clinical trials for its flagship monoclonal antibody, ICT01, and to further develop its expansive pipeline of immunomodulators targeting the butyrophilins super-family, alongside advancing additional immuno-oncology antibody programs toward clinical trials.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The biotechnology industry in France has witnessed substantial growth, propelled by advancements in research and development, particularly in the area of cancer therapies. Wit
Similar Deals
Wellington Partners
invested in
ImCheck Therapeutics
in 2019
in a Series B deal
Disclosed details
Transaction Size: $53M